Articles with public access mandates - Raymond P PerezLearn more
Not available anywhere: 1
TP53 Gene and Cancer Resistance in Elephants
RP Perez, T Komiya
JAMA 315 (16), 1789-1790, 2016
Mandates: US Department of Veterans Affairs
Available somewhere: 11
Phase Ib pilot study to evaluate reparixin in combination with weekly paclitaxel in patients with HER-2–negative metastatic breast cancer
AF Schott, LJ Goldstein, M Cristofanilli, PA Ruffini, S McCanna, ...
Clinical Cancer Research 23 (18), 5358-5365, 2017
Mandates: US National Institutes of Health
Safety and activity of mirvetuximab soravtansine (IMGN853), a folate receptor alpha–targeting antibody–drug conjugate, in platinum-resistant ovarian, fallopian tube, or primary …
KN Moore, LP Martin, DM O’Malley, UA Matulonis, JA Konner, RP Perez, ...
Journal of clinical oncology 35 (10), 1112-1118, 2017
Mandates: US National Institutes of Health
Phase 1 dose‐escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α‐targeting antibody‐drug conjugate, in patients with solid tumors
KN Moore, H Borghaei, DM O'Malley, W Jeong, SM Seward, TM Bauer, ...
Cancer 123 (16), 3080-3087, 2017
Mandates: US National Institutes of Health
Characterization of folate receptor alpha (FRα) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: a phase I expansion study of …
LP Martin, JA Konner, KN Moore, SM Seward, UA Matulonis, RP Perez, ...
Gynecologic oncology 147 (2), 402-407, 2017
Mandates: US National Institutes of Health
A phase Ib/II trial of the first-in-class anti-CXCR4 antibody ulocuplumab in combination with lenalidomide or bortezomib plus dexamethasone in relapsed multiple myeloma
IM Ghobrial, CJ Liu, RA Redd, RP Perez, R Baz, O Zavidij, ...
Clinical Cancer Research 26 (2), 344-353, 2020
Mandates: US National Institutes of Health
Extra-cellular Membrane Vesicles derived from 143B Osteosarcoma Cells contain Pro-osteoclastogenic Cargo: A Novel Mechanism for Mediating Bone Destruction in the Osteosarcoma …
R Garimella, L Washington, J Isaacson, J Vallejo, M Spence, O Tawfik, ...
Translational Oncology 7 (3), 331-340, 2014
Mandates: US National Institutes of Health
Sponsors’ and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials
R Perez, P Archdeacon, N Roach, R Goodwin, J Jarow, N Stuccio, ...
Clinical Trials, https://doi.org/10.1177/1740774517700640, 2017
Mandates: US National Institutes of Health
Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement …
RP Perez, S Finnigan, K Patel, S Whitney, A Forrest
JMIR Cancer 2 (2), e16, 2016
Mandates: US National Institutes of Health
Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics
T Komiya, S Yamamoto, A Roy, P McDonald, RP Perez
Translational lung cancer research 6 (5), 600-610, 2017
Mandates: US National Institutes of Health
The effect of sonidegib (LDE225) on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumours
DB Pooler, DB Ness, J Sarantopoulos, N Squittieri, S Ravichandran, ...
British Journal of Clinical Pharmacology 87 (3), 1291-1302, 2021
Mandates: US National Institutes of Health
Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies
RP Perez, E Chen, J Thaddeus Beck, K Shirai, D Neil Hayes, T Shen, ...
Pharmacology Research & Perspectives 7 (6), e00519, 2019
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program